PB-718 a dual agonist that activates both the GLP-1 receptor and the glucagon receptor
- 产品概览
- 作用机理
- 产品特点与优势
- 研究进展
-
PB-718 is a dual agonist that activates both the GLP-1 receptor and the glucagon receptor to produce synergistic weight loss effects. The Investigational New Drug (IND) application of PB-718 for obesity indication is in preparation.
-
PB-718是GLP-1受体及胰高血糖素受体双靶点激动剂的组合物,通过抑制食欲和增加能量消耗等机制,产生协同效应,有效减轻体重。
-
(1) 同时激活GLP-1受体及胰高血糖素受体,产生协同效应,从能量摄入和消耗两个角度控制体重
(2) 在临床前研究中展现了良好的减重效果,且安全性良好
-
PB-718处于IND申报准备阶段。